Treatment of Acute Pulmonary Coccidioidomycosis in Hematopoietic Stem Cell or Solid Organ Transplant Recipients

Clinical Scenario

This protocol applies to recipients of autologous or allogeneic hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) who present with acute pulmonary coccidioidomycosis that is very severe and/or rapidly progressing.

This immunocompromised population requires a specific, evidence-based management approach distinct from standard presentations.

Why Transplant Recipients Need a Dedicated Protocol

Autologous HSCT, allogeneic HSCT, and solid organ transplant recipients carry a substantially altered immune landscape. In this context, very severe or rapidly progressing acute pulmonary coccidioidomycosis demands prompt, structured intervention guided by recommendations specific to this patient group.

Treatment Approach (Partial Overview)

In this setting, the recommended approach begins with intravenous antifungal therapy as the initial intervention. The primary clinical goal is stabilization of the patient. The complete regimen — including agent selection, sequencing, and transition criteria — is available in the full structured protocol.